ARYZTA AG (ARZTF) Stock Competitors & Peer Comparison

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NSRGF has a market cap of 257.9B. Regarding current trading prices, ARZTF is priced at $62.68, while NSRGF trades at $100.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NSRGF's P/E ratio is 22.59. In terms of profitability, ARZTF's ROE is +0.23%, compared to NSRGF's ROE of +0.29%. Regarding short-term risk, ARZTF is less volatile compared to NSRGF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NSRGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NSRGY has a market cap of 255.4B. Regarding current trading prices, ARZTF is priced at $62.68, while NSRGY trades at $99.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NSRGY's P/E ratio is 22.37. In terms of profitability, ARZTF's ROE is +0.23%, compared to NSRGY's ROE of +0.29%. Regarding short-term risk, ARZTF is less volatile compared to NSRGY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NSRGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, DANOY has a market cap of 49B. Regarding current trading prices, ARZTF is priced at $62.68, while DANOY trades at $15.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas DANOY's P/E ratio is 23.49. In terms of profitability, ARZTF's ROE is +0.23%, compared to DANOY's ROE of +0.11%. Regarding short-term risk, ARZTF is less volatile compared to DANOY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check DANOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GPDNF has a market cap of 48.8B. Regarding current trading prices, ARZTF is priced at $62.68, while GPDNF trades at $76.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GPDNF's P/E ratio is 22.63. In terms of profitability, ARZTF's ROE is +0.23%, compared to GPDNF's ROE of +0.11%. Regarding short-term risk, ARZTF is less volatile compared to GPDNF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GPDNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, JBSAY has a market cap of 30.6B. Regarding current trading prices, ARZTF is priced at $62.68, while JBSAY trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas JBSAY's P/E ratio is 6.94. In terms of profitability, ARZTF's ROE is +0.23%, compared to JBSAY's ROE of +0.19%. Regarding short-term risk, ARZTF is less volatile compared to JBSAY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check JBSAY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, AJINF has a market cap of 27.8B. Regarding current trading prices, ARZTF is priced at $62.68, while AJINF trades at $29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas AJINF's P/E ratio is 33.72. In terms of profitability, ARZTF's ROE is +0.23%, compared to AJINF's ROE of +0.18%. Regarding short-term risk, ARZTF is less volatile compared to AJINF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check AJINF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ASBFY has a market cap of 18.2B. Regarding current trading prices, ARZTF is priced at $62.68, while ASBFY trades at $26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ASBFY's P/E ratio is 14.51. In terms of profitability, ARZTF's ROE is +0.23%, compared to ASBFY's ROE of +0.08%. Regarding short-term risk, ARZTF is less volatile compared to ASBFY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check ASBFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, JDEPF has a market cap of 17.7B. Regarding current trading prices, ARZTF is priced at $62.68, while JDEPF trades at $36.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas JDEPF's P/E ratio is 19.25. In terms of profitability, ARZTF's ROE is +0.23%, compared to JDEPF's ROE of +0.07%. Regarding short-term risk, ARZTF is less volatile compared to JDEPF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check JDEPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ASBFF has a market cap of 17.6B. Regarding current trading prices, ARZTF is priced at $62.68, while ASBFF trades at $25.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ASBFF's P/E ratio is 13.02. In terms of profitability, ARZTF's ROE is +0.23%, compared to ASBFF's ROE of +0.08%. Regarding short-term risk, ARZTF and ASBFF have similar daily volatility (0.00).Check ASBFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, WHGLY has a market cap of 14.4B. Regarding current trading prices, ARZTF is priced at $62.68, while WHGLY trades at $22.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas WHGLY's P/E ratio is 9.20. In terms of profitability, ARZTF's ROE is +0.23%, compared to WHGLY's ROE of +0.14%. Regarding short-term risk, ARZTF is less volatile compared to WHGLY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check WHGLY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, AJINY has a market cap of 14.4B. Regarding current trading prices, ARZTF is priced at $62.68, while AJINY trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas AJINY's P/E ratio is 117.46. In terms of profitability, ARZTF's ROE is +0.23%, compared to AJINY's ROE of +0.11%. Regarding short-term risk, ARZTF is less volatile compared to AJINY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check AJINY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, KRYAY has a market cap of 14.2B. Regarding current trading prices, ARZTF is priced at $62.68, while KRYAY trades at $88.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas KRYAY's P/E ratio is 19.26. In terms of profitability, ARZTF's ROE is +0.23%, compared to KRYAY's ROE of +0.11%. Regarding short-term risk, ARZTF is less volatile compared to KRYAY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check KRYAY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, BMBOY has a market cap of 14B. Regarding current trading prices, ARZTF is priced at $62.68, while BMBOY trades at $12.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas BMBOY's P/E ratio is 20.94. In terms of profitability, ARZTF's ROE is +0.23%, compared to BMBOY's ROE of +0.10%. Regarding short-term risk, ARZTF and BMBOY have similar daily volatility (0.00).Check BMBOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, WHGRF has a market cap of 13.6B. Regarding current trading prices, ARZTF is priced at $62.68, while WHGRF trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas WHGRF's P/E ratio is 8.83. In terms of profitability, ARZTF's ROE is +0.23%, compared to WHGRF's ROE of +0.14%. Regarding short-term risk, ARZTF is less volatile compared to WHGRF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check WHGRF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, KRYAF has a market cap of 13B. Regarding current trading prices, ARZTF is priced at $62.68, while KRYAF trades at $81.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas KRYAF's P/E ratio is 17.70. In terms of profitability, ARZTF's ROE is +0.23%, compared to KRYAF's ROE of +0.09%. Regarding short-term risk, ARZTF is less volatile compared to KRYAF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check KRYAF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GRBMF has a market cap of 12.8B. Regarding current trading prices, ARZTF is priced at $62.68, while GRBMF trades at $2.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GRBMF's P/E ratio is 19.87. In terms of profitability, ARZTF's ROE is +0.23%, compared to GRBMF's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to GRBMF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GRBMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SAPIF has a market cap of 12B. Regarding current trading prices, ARZTF is priced at $62.68, while SAPIF trades at $29.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SAPIF's P/E ratio is 25.02. In terms of profitability, ARZTF's ROE is +0.23%, compared to SAPIF's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to SAPIF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check SAPIF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ORKLF has a market cap of 10.4B. Regarding current trading prices, ARZTF is priced at $62.68, while ORKLF trades at $10.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ORKLF's P/E ratio is 15.66. In terms of profitability, ARZTF's ROE is +0.23%, compared to ORKLF's ROE of +0.24%. Regarding short-term risk, ARZTF is less volatile compared to ORKLF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check ORKLF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ORKLY has a market cap of 10.4B. Regarding current trading prices, ARZTF is priced at $62.68, while ORKLY trades at $10.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ORKLY's P/E ratio is 15.17. In terms of profitability, ARZTF's ROE is +0.23%, compared to ORKLY's ROE of +0.24%. Regarding short-term risk, ARZTF is less volatile compared to ORKLY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check ORKLY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SDPNF has a market cap of 10.3B. Regarding current trading prices, ARZTF is priced at $62.68, while SDPNF trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SDPNF's P/E ratio is 16.55. In terms of profitability, ARZTF's ROE is +0.23%, compared to SDPNF's ROE of +0.14%. Regarding short-term risk, ARZTF is less volatile compared to SDPNF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check SDPNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, BRZL has a market cap of 10.1B. Regarding current trading prices, ARZTF is priced at $62.68, while BRZL trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas BRZL's P/E ratio is N/A. In terms of profitability, ARZTF's ROE is +0.23%, compared to BRZL's ROE of +0.72%. Regarding short-term risk, ARZTF is less volatile compared to BRZL. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check BRZL's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, LOTBY has a market cap of 9.3B. Regarding current trading prices, ARZTF is priced at $62.68, while LOTBY trades at $114.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas LOTBY's P/E ratio is 46.54. In terms of profitability, ARZTF's ROE is +0.23%, compared to LOTBY's ROE of +0.21%. Regarding short-term risk, ARZTF is less volatile compared to LOTBY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check LOTBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TTAZF has a market cap of 8.8B. Regarding current trading prices, ARZTF is priced at $62.68, while TTAZF trades at $7.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TTAZF's P/E ratio is 77.60. In terms of profitability, ARZTF's ROE is +0.23%, compared to TTAZF's ROE of N/A. Regarding short-term risk, ARZTF and TTAZF have similar daily volatility (0.00).Check TTAZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, KIKOY has a market cap of 8.6B. Regarding current trading prices, ARZTF is priced at $62.68, while KIKOY trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas KIKOY's P/E ratio is 22.56. In terms of profitability, ARZTF's ROE is +0.23%, compared to KIKOY's ROE of +0.12%. Regarding short-term risk, ARZTF and KIKOY have similar daily volatility (0.00).Check KIKOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, KIKOF has a market cap of 8.6B. Regarding current trading prices, ARZTF is priced at $62.68, while KIKOF trades at $9.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas KIKOF's P/E ratio is 22.55. In terms of profitability, ARZTF's ROE is +0.23%, compared to KIKOF's ROE of +0.12%. Regarding short-term risk, ARZTF is less volatile compared to KIKOF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check KIKOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CIADF has a market cap of 8.5B. Regarding current trading prices, ARZTF is priced at $62.68, while CIADF trades at $2.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CIADF's P/E ratio is 36.83. In terms of profitability, ARZTF's ROE is +0.23%, compared to CIADF's ROE of +0.04%. Regarding short-term risk, ARZTF is less volatile compared to CIADF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CIADF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CIADY has a market cap of 8.2B. Regarding current trading prices, ARZTF is priced at $62.68, while CIADY trades at $21.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CIADY's P/E ratio is 36.34. In terms of profitability, ARZTF's ROE is +0.23%, compared to CIADY's ROE of +0.04%. Regarding short-term risk, ARZTF and CIADY have similar daily volatility (0.00).Check CIADY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TCYMF has a market cap of 8.2B. Regarding current trading prices, ARZTF is priced at $62.68, while TCYMF trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TCYMF's P/E ratio is 14.50. In terms of profitability, ARZTF's ROE is +0.23%, compared to TCYMF's ROE of +0.23%. Regarding short-term risk, ARZTF and TCYMF have similar daily volatility (0.00).Check TCYMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TYCMY has a market cap of 7.6B. Regarding current trading prices, ARZTF is priced at $62.68, while TYCMY trades at $28.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TYCMY's P/E ratio is 11.44. In terms of profitability, ARZTF's ROE is +0.23%, compared to TYCMY's ROE of +0.23%. Regarding short-term risk, ARZTF is less volatile compared to TYCMY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TYCMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, FNEVY has a market cap of 7.6B. Regarding current trading prices, ARZTF is priced at $62.68, while FNEVY trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas FNEVY's P/E ratio is 13.00. In terms of profitability, ARZTF's ROE is +0.23%, compared to FNEVY's ROE of +0.05%. Regarding short-term risk, ARZTF and FNEVY have similar daily volatility (0.00).Check FNEVY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TATYY has a market cap of 7.1B. Regarding current trading prices, ARZTF is priced at $62.68, while TATYY trades at $30.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TATYY's P/E ratio is 25.77. In terms of profitability, ARZTF's ROE is +0.23%, compared to TATYY's ROE of +0.06%. Regarding short-term risk, ARZTF is less volatile compared to TATYY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TATYY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SGLJF has a market cap of 7B. Regarding current trading prices, ARZTF is priced at $62.68, while SGLJF trades at $47.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SGLJF's P/E ratio is 34.69. In terms of profitability, ARZTF's ROE is +0.23%, compared to SGLJF's ROE of +0.14%. Regarding short-term risk, ARZTF and SGLJF have similar daily volatility (0.00).Check SGLJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ARHUF has a market cap of 6.8B. Regarding current trading prices, ARZTF is priced at $62.68, while ARHUF trades at $26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ARHUF's P/E ratio is 18.44. In terms of profitability, ARZTF's ROE is +0.23%, compared to ARHUF's ROE of +0.18%. Regarding short-term risk, ARZTF and ARHUF have similar daily volatility (0.00).Check ARHUF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TSUKF has a market cap of 6.8B. Regarding current trading prices, ARZTF is priced at $62.68, while TSUKF trades at $69.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TSUKF's P/E ratio is 15.64. In terms of profitability, ARZTF's ROE is +0.23%, compared to TSUKF's ROE of +0.14%. Regarding short-term risk, ARZTF is less volatile compared to TSUKF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TSUKF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, DLLFF has a market cap of 6.5B. Regarding current trading prices, ARZTF is priced at $62.68, while DLLFF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas DLLFF's P/E ratio is 14.00. In terms of profitability, ARZTF's ROE is +0.23%, compared to DLLFF's ROE of N/A. Regarding short-term risk, ARZTF and DLLFF have similar daily volatility (0.00).Check DLLFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GCHOY has a market cap of 6.5B. Regarding current trading prices, ARZTF is priced at $62.68, while GCHOY trades at $10.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GCHOY's P/E ratio is 27.31. In terms of profitability, ARZTF's ROE is +0.23%, compared to GCHOY's ROE of +0.13%. Regarding short-term risk, ARZTF is less volatile compared to GCHOY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GCHOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, WWNTF has a market cap of 6.4B. Regarding current trading prices, ARZTF is priced at $62.68, while WWNTF trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas WWNTF's P/E ratio is 10.80. In terms of profitability, ARZTF's ROE is +0.23%, compared to WWNTF's ROE of +0.24%. Regarding short-term risk, ARZTF and WWNTF have similar daily volatility (0.00).Check WWNTF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, WWNTY has a market cap of 6.3B. Regarding current trading prices, ARZTF is priced at $62.68, while WWNTY trades at $27.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas WWNTY's P/E ratio is 10.17. In terms of profitability, ARZTF's ROE is +0.23%, compared to WWNTY's ROE of +0.23%. Regarding short-term risk, ARZTF and WWNTY have similar daily volatility (0.00).Check WWNTY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GLAPY has a market cap of 6.3B. Regarding current trading prices, ARZTF is priced at $62.68, while GLAPY trades at $129.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GLAPY's P/E ratio is 35.76. In terms of profitability, ARZTF's ROE is +0.23%, compared to GLAPY's ROE of +0.09%. Regarding short-term risk, ARZTF is less volatile compared to GLAPY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GLAPY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GPAGF has a market cap of 6.2B. Regarding current trading prices, ARZTF is priced at $62.68, while GPAGF trades at $18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GPAGF's P/E ratio is 11.75. In terms of profitability, ARZTF's ROE is +0.23%, compared to GPAGF's ROE of +0.23%. Regarding short-term risk, ARZTF and GPAGF have similar daily volatility (0.00).Check GPAGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, MEJHY has a market cap of 6.1B. Regarding current trading prices, ARZTF is priced at $62.68, while MEJHY trades at $11.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas MEJHY's P/E ratio is 28.19. In terms of profitability, ARZTF's ROE is +0.23%, compared to MEJHY's ROE of +0.05%. Regarding short-term risk, ARZTF is less volatile compared to MEJHY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check MEJHY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TSUKY has a market cap of 6.1B. Regarding current trading prices, ARZTF is priced at $62.68, while TSUKY trades at $62.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TSUKY's P/E ratio is 14.01. In terms of profitability, ARZTF's ROE is +0.23%, compared to TSUKY's ROE of +0.14%. Regarding short-term risk, ARZTF is less volatile compared to TSUKY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TSUKY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GLAPF has a market cap of 6B. Regarding current trading prices, ARZTF is priced at $62.68, while GLAPF trades at $24.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GLAPF's P/E ratio is 34.40. In terms of profitability, ARZTF's ROE is +0.23%, compared to GLAPF's ROE of +0.09%. Regarding short-term risk, ARZTF and GLAPF have similar daily volatility (0.00).Check GLAPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, EMLZF has a market cap of 5.6B. Regarding current trading prices, ARZTF is priced at $62.68, while EMLZF trades at $1,054.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas EMLZF's P/E ratio is 19.80. In terms of profitability, ARZTF's ROE is +0.23%, compared to EMLZF's ROE of +0.22%. Regarding short-term risk, ARZTF is less volatile compared to EMLZF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check EMLZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NSLYF has a market cap of 5.6B. Regarding current trading prices, ARZTF is priced at $62.68, while NSLYF trades at $23.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NSLYF's P/E ratio is 40.27. In terms of profitability, ARZTF's ROE is +0.23%, compared to NSLYF's ROE of +0.93%. Regarding short-term risk, ARZTF and NSLYF have similar daily volatility (0.00).Check NSLYF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, MEJHF has a market cap of 5.5B. Regarding current trading prices, ARZTF is priced at $62.68, while MEJHF trades at $20.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas MEJHF's P/E ratio is 17.02. In terms of profitability, ARZTF's ROE is +0.23%, compared to MEJHF's ROE of +0.05%. Regarding short-term risk, ARZTF is less volatile compared to MEJHF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check MEJHF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SMPFF has a market cap of 5.2B. Regarding current trading prices, ARZTF is priced at $62.68, while SMPFF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SMPFF's P/E ratio is 13.38. In terms of profitability, ARZTF's ROE is +0.23%, compared to SMPFF's ROE of +0.18%. Regarding short-term risk, ARZTF and SMPFF have similar daily volatility (0.00).Check SMPFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ALFFF has a market cap of 5.2B. Regarding current trading prices, ARZTF is priced at $62.68, while ALFFF trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ALFFF's P/E ratio is 11.63. In terms of profitability, ARZTF's ROE is +0.23%, compared to ALFFF's ROE of +0.41%. Regarding short-term risk, ARZTF is less volatile compared to ALFFF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check ALFFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NFPDF has a market cap of 5B. Regarding current trading prices, ARZTF is priced at $62.68, while NFPDF trades at $17.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NFPDF's P/E ratio is 17.78. In terms of profitability, ARZTF's ROE is +0.23%, compared to NFPDF's ROE of +0.12%. Regarding short-term risk, ARZTF is less volatile compared to NFPDF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NFPDF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PIFFY has a market cap of 4.9B. Regarding current trading prices, ARZTF is priced at $62.68, while PIFFY trades at $8.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PIFFY's P/E ratio is 9.73. In terms of profitability, ARZTF's ROE is +0.23%, compared to PIFFY's ROE of +0.18%. Regarding short-term risk, ARZTF is less volatile compared to PIFFY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PIFFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, IOIOF has a market cap of 4.8B. Regarding current trading prices, ARZTF is priced at $62.68, while IOIOF trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas IOIOF's P/E ratio is 12.64. In terms of profitability, ARZTF's ROE is +0.23%, compared to IOIOF's ROE of +0.13%. Regarding short-term risk, ARZTF and IOIOF have similar daily volatility (0.00).Check IOIOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CFEIY has a market cap of 4B. Regarding current trading prices, ARZTF is priced at $62.68, while CFEIY trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CFEIY's P/E ratio is 14.16. In terms of profitability, ARZTF's ROE is +0.23%, compared to CFEIY's ROE of +0.08%. Regarding short-term risk, ARZTF is less volatile compared to CFEIY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CFEIY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NIPMY has a market cap of 4B. Regarding current trading prices, ARZTF is priced at $62.68, while NIPMY trades at $21.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NIPMY's P/E ratio is 20.39. In terms of profitability, ARZTF's ROE is +0.23%, compared to NIPMY's ROE of +0.07%. Regarding short-term risk, ARZTF and NIPMY have similar daily volatility (0.00).Check NIPMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CHFLF has a market cap of 3.8B. Regarding current trading prices, ARZTF is priced at $62.68, while CHFLF trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CHFLF's P/E ratio is 14.33. In terms of profitability, ARZTF's ROE is +0.23%, compared to CHFLF's ROE of +0.08%. Regarding short-term risk, ARZTF is less volatile compared to CHFLF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CHFLF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CRWKF has a market cap of 3.7B. Regarding current trading prices, ARZTF is priced at $62.68, while CRWKF trades at $69.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CRWKF's P/E ratio is 17.84. In terms of profitability, ARZTF's ROE is +0.23%, compared to CRWKF's ROE of +0.15%. Regarding short-term risk, ARZTF is less volatile compared to CRWKF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CRWKF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PIFMF has a market cap of 3.7B. Regarding current trading prices, ARZTF is priced at $62.68, while PIFMF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PIFMF's P/E ratio is 8.40. In terms of profitability, ARZTF's ROE is +0.23%, compared to PIFMF's ROE of +0.15%. Regarding short-term risk, ARZTF is less volatile compared to PIFMF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PIFMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, YMZBY has a market cap of 3.5B. Regarding current trading prices, ARZTF is priced at $62.68, while YMZBY trades at $180.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas YMZBY's P/E ratio is 14.08. In terms of profitability, ARZTF's ROE is +0.23%, compared to YMZBY's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to YMZBY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check YMZBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TATYF has a market cap of 3.3B. Regarding current trading prices, ARZTF is priced at $62.68, while TATYF trades at $7.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TATYF's P/E ratio is 25.86. In terms of profitability, ARZTF's ROE is +0.23%, compared to TATYF's ROE of +0.06%. Regarding short-term risk, ARZTF and TATYF have similar daily volatility (0.00).Check TATYF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, EBRPF has a market cap of 3.2B. Regarding current trading prices, ARZTF is priced at $62.68, while EBRPF trades at $20.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas EBRPF's P/E ratio is 13.96. In terms of profitability, ARZTF's ROE is +0.23%, compared to EBRPF's ROE of +0.09%. Regarding short-term risk, ARZTF and EBRPF have similar daily volatility (0.00).Check EBRPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NSFMF has a market cap of 3.2B. Regarding current trading prices, ARZTF is priced at $62.68, while NSFMF trades at $11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NSFMF's P/E ratio is 14.20. In terms of profitability, ARZTF's ROE is +0.23%, compared to NSFMF's ROE of +0.06%. Regarding short-term risk, ARZTF is less volatile compared to NSFMF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NSFMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NHFOF has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $62.68, while NHFOF trades at $33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NHFOF's P/E ratio is 18.54. In terms of profitability, ARZTF's ROE is +0.23%, compared to NHFOF's ROE of +0.07%. Regarding short-term risk, ARZTF is less volatile compared to NHFOF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NHFOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PIFMY has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $62.68, while PIFMY trades at $17.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PIFMY's P/E ratio is 5.12. In terms of profitability, ARZTF's ROE is +0.23%, compared to PIFMY's ROE of +0.15%. Regarding short-term risk, ARZTF is less volatile compared to PIFMY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PIFMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NCHEY has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $62.68, while NCHEY trades at $12.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NCHEY's P/E ratio is 18.06. In terms of profitability, ARZTF's ROE is +0.23%, compared to NCHEY's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to NCHEY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NCHEY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TBLMF has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $62.68, while TBLMF trades at $20.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TBLMF's P/E ratio is 12.97. In terms of profitability, ARZTF's ROE is +0.23%, compared to TBLMF's ROE of +0.31%. Regarding short-term risk, ARZTF is less volatile compared to TBLMF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TBLMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, LYSFY has a market cap of 2.9B. Regarding current trading prices, ARZTF is priced at $62.68, while LYSFY trades at $9.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas LYSFY's P/E ratio is 26.49. In terms of profitability, ARZTF's ROE is +0.23%, compared to LYSFY's ROE of +0.06%. Regarding short-term risk, ARZTF and LYSFY have similar daily volatility (0.00).Check LYSFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SUEZY has a market cap of 2.9B. Regarding current trading prices, ARZTF is priced at $62.68, while SUEZY trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SUEZY's P/E ratio is -6.40. In terms of profitability, ARZTF's ROE is +0.23%, compared to SUEZY's ROE of -0.13%. Regarding short-term risk, ARZTF is less volatile compared to SUEZY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check SUEZY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ACOPF has a market cap of 2.9B. Regarding current trading prices, ARZTF is priced at $62.68, while ACOPF trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ACOPF's P/E ratio is 21.94. In terms of profitability, ARZTF's ROE is +0.23%, compared to ACOPF's ROE of +0.16%. Regarding short-term risk, ARZTF is less volatile compared to ACOPF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check ACOPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, MRRTY has a market cap of 2.9B. Regarding current trading prices, ARZTF is priced at $62.68, while MRRTY trades at $3.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas MRRTY's P/E ratio is 11.03. In terms of profitability, ARZTF's ROE is +0.23%, compared to MRRTY's ROE of +0.97%. Regarding short-term risk, ARZTF is less volatile compared to MRRTY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check MRRTY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CBCFF has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $62.68, while CBCFF trades at $23.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CBCFF's P/E ratio is 21.90. In terms of profitability, ARZTF's ROE is +0.23%, compared to CBCFF's ROE of +0.08%. Regarding short-term risk, ARZTF is less volatile compared to CBCFF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CBCFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ACOPY has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $62.68, while ACOPY trades at $3.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ACOPY's P/E ratio is 21.28. In terms of profitability, ARZTF's ROE is +0.23%, compared to ACOPY's ROE of +0.16%. Regarding short-term risk, ARZTF and ACOPY have similar daily volatility (0.00).Check ACOPY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PRBZF has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $62.68, while PRBZF trades at $62.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PRBZF's P/E ratio is 98.56. In terms of profitability, ARZTF's ROE is +0.23%, compared to PRBZF's ROE of +0.02%. Regarding short-term risk, ARZTF is less volatile compared to PRBZF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PRBZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, EBRPY has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $62.68, while EBRPY trades at $17.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas EBRPY's P/E ratio is 20.34. In terms of profitability, ARZTF's ROE is +0.23%, compared to EBRPY's ROE of +0.06%. Regarding short-term risk, ARZTF and EBRPY have similar daily volatility (0.00).Check EBRPY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, FPAFY has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $62.68, while FPAFY trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas FPAFY's P/E ratio is 4.12. In terms of profitability, ARZTF's ROE is +0.23%, compared to FPAFY's ROE of +0.15%. Regarding short-term risk, ARZTF is less volatile compared to FPAFY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check FPAFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, FPAFF has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $62.68, while FPAFF trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas FPAFF's P/E ratio is 4.20. In terms of profitability, ARZTF's ROE is +0.23%, compared to FPAFF's ROE of +0.15%. Regarding short-term risk, ARZTF is less volatile compared to FPAFF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check FPAFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, MLFNF has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $62.68, while MLFNF trades at $21.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas MLFNF's P/E ratio is 52.44. In terms of profitability, ARZTF's ROE is +0.23%, compared to MLFNF's ROE of +0.37%. Regarding short-term risk, ARZTF is less volatile compared to MLFNF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check MLFNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, NISUY has a market cap of 2.6B. Regarding current trading prices, ARZTF is priced at $62.68, while NISUY trades at $86.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas NISUY's P/E ratio is 15.44. In terms of profitability, ARZTF's ROE is +0.23%, compared to NISUY's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to NISUY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check NISUY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, LYSFF has a market cap of 2.6B. Regarding current trading prices, ARZTF is priced at $62.68, while LYSFF trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas LYSFF's P/E ratio is 23.89. In terms of profitability, ARZTF's ROE is +0.23%, compared to LYSFF's ROE of +0.06%. Regarding short-term risk, ARZTF and LYSFF have similar daily volatility (0.00).Check LYSFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, SUEZF has a market cap of 2.5B. Regarding current trading prices, ARZTF is priced at $62.68, while SUEZF trades at $12.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas SUEZF's P/E ratio is -5.44. In terms of profitability, ARZTF's ROE is +0.23%, compared to SUEZF's ROE of -0.14%. Regarding short-term risk, ARZTF is less volatile compared to SUEZF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check SUEZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PRRFY has a market cap of 2.3B. Regarding current trading prices, ARZTF is priced at $62.68, while PRRFY trades at $13.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PRRFY's P/E ratio is 12.72. In terms of profitability, ARZTF's ROE is +0.23%, compared to PRRFY's ROE of +0.19%. Regarding short-term risk, ARZTF is less volatile compared to PRRFY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PRRFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, UVRBF has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $62.68, while UVRBF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas UVRBF's P/E ratio is 12.50. In terms of profitability, ARZTF's ROE is +0.23%, compared to UVRBF's ROE of +0.08%. Regarding short-term risk, ARZTF and UVRBF have similar daily volatility (0.00).Check UVRBF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, CLBEY has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $62.68, while CLBEY trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas CLBEY's P/E ratio is 19.73. In terms of profitability, ARZTF's ROE is +0.23%, compared to CLBEY's ROE of +0.09%. Regarding short-term risk, ARZTF is less volatile compared to CLBEY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check CLBEY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, PFODF has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $62.68, while PFODF trades at $2.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas PFODF's P/E ratio is 11.52. In terms of profitability, ARZTF's ROE is +0.23%, compared to PFODF's ROE of +0.16%. Regarding short-term risk, ARZTF is less volatile compared to PFODF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check PFODF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GRPBF has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $62.68, while GRPBF trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GRPBF's P/E ratio is N/A. In terms of profitability, ARZTF's ROE is +0.23%, compared to GRPBF's ROE of N/A. Regarding short-term risk, ARZTF and GRPBF have similar daily volatility (0.00).Check GRPBF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, UVRBY has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $62.68, while UVRBY trades at $9.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas UVRBY's P/E ratio is 12.76. In terms of profitability, ARZTF's ROE is +0.23%, compared to UVRBY's ROE of +0.08%. Regarding short-term risk, ARZTF is less volatile compared to UVRBY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check UVRBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, ARZTY has a market cap of 2B. Regarding current trading prices, ARZTF is priced at $62.68, while ARZTY trades at $7.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas ARZTY's P/E ratio is 14.98. In terms of profitability, ARZTF's ROE is +0.23%, compared to ARZTY's ROE of +0.22%. Regarding short-term risk, ARZTF and ARZTY have similar daily volatility (0.00).Check ARZTY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, YNNHF has a market cap of 1.9B. Regarding current trading prices, ARZTF is priced at $62.68, while YNNHF trades at $1.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas YNNHF's P/E ratio is 15.32. In terms of profitability, ARZTF's ROE is +0.23%, compared to YNNHF's ROE of +0.18%. Regarding short-term risk, ARZTF is less volatile compared to YNNHF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check YNNHF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, HOFJF has a market cap of 1.8B. Regarding current trading prices, ARZTF is priced at $62.68, while HOFJF trades at $19.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas HOFJF's P/E ratio is 23.90. In terms of profitability, ARZTF's ROE is +0.23%, compared to HOFJF's ROE of +0.03%. Regarding short-term risk, ARZTF is less volatile compared to HOFJF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check HOFJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TBLMY has a market cap of 1.7B. Regarding current trading prices, ARZTF is priced at $62.68, while TBLMY trades at $10.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TBLMY's P/E ratio is 12.02. In terms of profitability, ARZTF's ROE is +0.23%, compared to TBLMY's ROE of +0.17%. Regarding short-term risk, ARZTF and TBLMY have similar daily volatility (0.00).Check TBLMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, AVSFY has a market cap of 1.7B. Regarding current trading prices, ARZTF is priced at $62.68, while AVSFY trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas AVSFY's P/E ratio is 12.32. In terms of profitability, ARZTF's ROE is +0.23%, compared to AVSFY's ROE of +0.46%. Regarding short-term risk, ARZTF and AVSFY have similar daily volatility (0.00).Check AVSFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, FNEVF has a market cap of 1.7B. Regarding current trading prices, ARZTF is priced at $62.68, while FNEVF trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas FNEVF's P/E ratio is 16.29. In terms of profitability, ARZTF's ROE is +0.23%, compared to FNEVF's ROE of +0.05%. Regarding short-term risk, ARZTF is less volatile compared to FNEVF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check FNEVF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TUFBY has a market cap of 1.4B. Regarding current trading prices, ARZTF is priced at $62.68, while TUFBY trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TUFBY's P/E ratio is 10.01. In terms of profitability, ARZTF's ROE is +0.23%, compared to TUFBY's ROE of +0.10%. Regarding short-term risk, ARZTF and TUFBY have similar daily volatility (0.00).Check TUFBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, HLFGY has a market cap of 1.4B. Regarding current trading prices, ARZTF is priced at $62.68, while HLFGY trades at $15.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas HLFGY's P/E ratio is 24.16. In terms of profitability, ARZTF's ROE is +0.23%, compared to HLFGY's ROE of +0.16%. Regarding short-term risk, ARZTF is less volatile compared to HLFGY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check HLFGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GNCGY has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $62.68, while GNCGY trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GNCGY's P/E ratio is 93.73. In terms of profitability, ARZTF's ROE is +0.23%, compared to GNCGY's ROE of +0.01%. Regarding short-term risk, ARZTF is less volatile compared to GNCGY. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GNCGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, AKEJF has a market cap of 1.2B. Regarding current trading prices, ARZTF is priced at $62.68, while AKEJF trades at $37.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas AKEJF's P/E ratio is 19.95. In terms of profitability, ARZTF's ROE is +0.23%, compared to AKEJF's ROE of +0.06%. Regarding short-term risk, ARZTF is less volatile compared to AKEJF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check AKEJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GNCGF has a market cap of 1.2B. Regarding current trading prices, ARZTF is priced at $62.68, while GNCGF trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GNCGF's P/E ratio is 89.00. In terms of profitability, ARZTF's ROE is +0.23%, compared to GNCGF's ROE of +0.01%. Regarding short-term risk, ARZTF is less volatile compared to GNCGF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GNCGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, BNGRF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $62.68, while BNGRF trades at $82.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas BNGRF's P/E ratio is 12.48. In terms of profitability, ARZTF's ROE is +0.23%, compared to BNGRF's ROE of +0.04%. Regarding short-term risk, ARZTF and BNGRF have similar daily volatility (0.00).Check BNGRF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GUZOF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $62.68, while GUZOF trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GUZOF's P/E ratio is 11.35. In terms of profitability, ARZTF's ROE is +0.23%, compared to GUZOF's ROE of +2.38%. Regarding short-term risk, ARZTF is less volatile compared to GUZOF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check GUZOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, TUFUF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $62.68, while TUFUF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas TUFUF's P/E ratio is 7.07. In terms of profitability, ARZTF's ROE is +0.23%, compared to TUFUF's ROE of +0.10%. Regarding short-term risk, ARZTF is less volatile compared to TUFUF. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check TUFUF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 1.9B. In comparison, GBFBF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $62.68, while GBFBF trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 522.33, whereas GBFBF's P/E ratio is 12.38. In terms of profitability, ARZTF's ROE is +0.23%, compared to GBFBF's ROE of N/A. Regarding short-term risk, ARZTF and GBFBF have similar daily volatility (0.00).Check GBFBF's competition here